

research program, and the benefits of each company's strategic plans and focus. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the research programs for these targets or using the technology licensed from Inhibrx will be unsuccessful and not result in any viable product candidates, the risk that our collaboration with Inhibrx will not continue or will not be successful, the risk of cessation or delay of any planned clinical studies and/or our development of our product candidates, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Inhibrx Forward-Looking Statements

Certain statements in this press release are forward looking statements that involve a number of risks and uncertainties. These statements include statements about Inhibrx's strategy, therapeutic candidates, including its sdAb platform. These statements represent Inhibrx's judgements and expectations as of the date of this release. Actual results may differ due to a number of factors, including, but not limited to, the potential success and efficacy of Inhibrx's therapeutic candidates. Inhibrx disclaims any intent or obligation to update these forward looking statements, other than as may be required by applicable law.

Contacts

For bluebird bio:

Investors:

Elizabeth Pingpank, 617-914-8736

epingpank@bluebirdbio.com

or

Media:

Jenn Snyder, 617-448-0281

jsnyder@bluebirdbio.com

For Inhibrx:

Amy Conrad

Juniper Point

amy@juniper-point.com

858-366-3243

<https://inhibrxbiosciences.investorroom.com/2019-01-07-bluebird-bio-and-Inhibrx-Announce-Collaboration-to-Research-Develop-and-Commercialize-CAR-T-Cell-Immunotherapies>